Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Exploring Novel Clinical Trial Designs for Gene-Based Therapies: Proceedings of a Workshop

Washington (DC): National Academies Press (US); 2020 Apr 9.
Free Books & Documents
Review

Exploring Novel Clinical Trial Designs for Gene-Based Therapies: Proceedings of a Workshop

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Regenerative Medicine.
Free Books & Documents

Excerpt

Recognizing the potential design complexities and ethical issues associated with clinical trials for gene therapies, the Forum on Regenerative Medicine of the National Academies of Sciences, Engineering, and Medicine held a 1-day workshop in Washington, DC, on November 13, 2019. Speakers at the workshop discussed patient recruitment and selection for gene-based clinical trials, explored how the safety of new therapies is assessed, reviewed the challenges involving dose escalation, and spoke about ethical issues such as informed consent and the role of clinicians in recommending trials as options to their patients. The workshop also included discussions of topics related to gene therapies in the context of other available and potentially curative treatments, such as bone marrow transplantation for hemoglobinopathies. This publication summarizes the presentation and discussion of the workshop.

PubMed Disclaimer

Grants and funding

This activity was supported by contracts between the National Academy of Sciences and Advanced Regenerative Manufacturing Institute; Akron Biotech; Alliance for Regenerative Medicine; American Society of Gene & Cell Therapy; Burroughs Wellcome Fund; California Institute for Regenerative Medicine; Centre for Commercialization of Regenerative Medicine; Department of Veterans Affairs (Contract No. VA268-16-C-0051); Food and Drug Administration (Grant #1R13FD0066—14-01); GE Healthcare; International Society for Cell & Gene Therapy; International Society for Stem Cell Research; Johnson & Johnson; The Michael J. Fox Foundation for Parkinson's Research; National Institute of Standards and Technology; National Institutes of Health: National Institute of Dental and Craniofacial Research (Contract No. HHSN263201800029I; Order No. 75N98019F00847), National Institute of Diabetes and Digestive and Kidney Diseases (PO No. 75N94019P00304); The New York Stem Cell Foundation; Parkinson's Foundation; Sanofi (Contract No. 55630791); and United Therapeutics Corporation (Contract No. 10003921). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.

LinkOut - more resources